Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;17(3):18.
doi: 10.1007/s11882-017-0687-0.

Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles

Harold S Nelson  1 , Moises A Calderon  2 , David I Bernstein  3 , Thomas B Casale  4 , Stephen R Durham  2 , Jens S Andersen  5 , Robert Esch  6 , Linda S Cox  7 , Hendrik Nolte  5
Affiliations
Review

Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles

Harold S Nelson et al. Curr Allergy Asthma Rep. 2017 Mar.

Abstract

Progress has been made in the harmonization of efficacy and safety outcome measures for allergen immunotherapy (AIT) trials, but unresolved issues still remain. Furthermore, there are discrepancies in recommendations from professional medical societies and regulatory agencies regarding requirements for AIT trials. In this article, we reviewed published recommendations and current data from recent clinical trials, as well as the criteria applied by regulatory authorities for approval of AIT products, to provide updated considerations for conducting phase 3 AIT trials. Topics discussed include analysis of outcomes and trial designs for pediatric and asthma indications, as well as trial designs for perennial allergic rhinoconjunctivitis. In addition, the need for harmonization of safety reporting is emphasized. Considerations presented in this article may further effort to find common ground among professional medical societies and government agencies in developing future recommendations for AIT trial design.

Keywords: Allergic rhinitis; Immunotherapy and tolerance induction; Regulatory aspects; Trial design.

PubMed Disclaimer

References

    1. J Allergy Clin Immunol. 2011 Jan;127(1):64-71, 71.e1-4 - PubMed
    1. Curr Allergy Asthma Rep. 2004 Nov;4(6):439-46 - PubMed
    1. Allergy. 2011 Jun;66(6):765-74 - PubMed
    1. Allergy. 2006;61 Suppl 81:24-8 - PubMed
    1. Clin Exp Otorhinolaryngol. 2009 Sep;2(3):136-40 - PubMed

MeSH terms

LinkOut - more resources